A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

Eligibility Criteria

• 1. Written informed consent and HIPAA authorization for release of personal health information
• 2. Age ≥ 18 years and ≤ 70 years at the time of consent
• 3. Histological confirmation of stage IS or IIA or higher testicular or germ cell cancer. Primary mediastinal and retroperitoneal GCT are allowed. Seminoma and non-seminoma histologies are allowed.
• 4. Performance Status (PS) of ECOG 0-2 at the time of enrollment
• 5. At least one of the following "high risk" of VTE features:
• 6. Planning or recently started 3-4 cycles of standard of care front-line cisplatin-based chemotherapy (bleomycin, etoposide, and platinum \[BEP\], etoposide and cisplatin \[EP\], or etoposide, ifosfamide, and cisplatin \[VIP\]). Note: ASA should be initiated no later than 2 weeks after initiation of standard front-line chemotherapy.
• 7. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
• 8. Ability to swallow oral medications
• 1. Receiving chemotherapy in adjuvant setting
• 2. Prior VTE/PE
• 3. Currently taking anticoagulation or antiplatelet therapy. Non-steroidal anti-inflammatory drug (NSAID) use for pain is allowed
• 4. Prior indication for anticoagulation or anticoagulation contraindicated (e.g., active bleed or risk of bleeding, such as history of gastrointestinal ulcers)
• 5. Allergy to ASA